Xolair Uni Eropa - Sloven - EMA (European Medicines Agency)

xolair

novartis europharm limited - omalizumab - asthma; urticaria - zdravila za obstruktivne pljučne bolezni, - alergijske asthmaxolair je navedeno pri odraslih, mladostnikih in otrocih (6 do.

Paxene Uni Eropa - Sloven - EMA (European Medicines Agency)

paxene

norton healthcare ltd. - paklitaksel - sarcoma, kaposi; carcinoma, non-small-cell lung; ovarian neoplasms; breast neoplasms - antineoplastična sredstva - paxene je indiciran za zdravljenje bolnikov z:• napredno za aidsom kaposi ' s sarkom (aids-cs), ki je ni pred liposomal anthracycline terapije;• metastatskim karcinom dojk (mbc), ki je ni, ali pa niso kandidati za standardne anthracycline-ki vsebujejo terapije;• napredno karcinom iz jajčnikov (aoc) ali z preostale bolezni (> 1 cm) po začetnem laparotomija, v kombinaciji z cisplatin kot prvo linijo zdravljenja;• metastatskim karcinom iz jajčnikov (moc) po izpadu platinum, ki vsebujejo kombinacijo terapija brez taxanes kot drugi liniji zdravljenja;• non-small cell karcinom pljuč (nsclc), ki niso kandidati za potencialno kurativno operacijo in/ali obsevanjem, v kombinaciji z cisplatin. omejeni podatki o učinkovitosti podpirajo to indikacijo (glejte poglavje 5).

Zevalin Uni Eropa - Sloven - EMA (European Medicines Agency)

zevalin

ceft biopharma s.r.o. - ibritumomab tiuksetan - limfom, folikularni - terapevtski radiofarmacevtiki - zdravilo zevalin je indicirano pri odraslih. [90y]-radioaktivno označiti zevalin je označen kot konsolidacije zdravljenje po odpustu indukcije pri predhodno nezdravljenih bolnikih s folikularni limfom. koristi zevalin naslednje rituksimaba v kombinaciji s kemoterapijo ni bila ugotovljena. [90y]-radioaktivno označiti zevalin je indiciran za zdravljenje odraslih bolnikov z rituksimabom relapsedorrefractory cd20+ folikularni b-celic non-hodgkinova limfomi (nhl).

Hexvix 85 mg prašek in vehikel za intravezikalno raztopino Slovenia - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

hexvix 85 mg prašek in vehikel za intravezikalno raztopino

ipsen pharma - heksaminolevulinat - prašek in vehikel za intravezikalno raztopino - heksaminolevulinat 85 mg / 1 viala - drugi diagnostiki

Bortezomib Ebewe 3,5 mg prašek za raztopino za injiciranje Slovenia - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

bortezomib ebewe 3,5 mg prašek za raztopino za injiciranje

ebewe pharma - bortezomib - prašek za raztopino za injiciranje - bortezomib 3,5 mg / 1 viala - bortezomib

Kyntheum Uni Eropa - Sloven - EMA (European Medicines Agency)

kyntheum

leo pharma a/s - brodalumab - psoriaza - imunosupresivi - kyntheum je indiciran za zdravljenje zmerne do hude psoriaze v plakih pri odraslih bolnikih, ki so kandidati za sistemsko zdravljenje.

Evenity Uni Eropa - Sloven - EMA (European Medicines Agency)

evenity

ucb pharma s.a. - romosozumab - osteoporoza - zdravila za zdravljenje bolezni kosti - evenity je navedeno v zdravljenje hude osteoporoze pri ženskah po menopavzi, ki imajo visoko tveganje za zlom.

Reblozyl Uni Eropa - Sloven - EMA (European Medicines Agency)

reblozyl

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - drugi antianemic priprave - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.

Bimzelx Uni Eropa - Sloven - EMA (European Medicines Agency)

bimzelx

ucb pharma s.a.   - bimekizumab - psoriaza - imunosupresivi - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Arexvy Uni Eropa - Sloven - EMA (European Medicines Agency)

arexvy

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - infekcije respiratornih sincicijskih virusov - cepiva - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.